Sanofi Jumps As Dupixent Nears $5 Billion In Sales; Trump Drug Talks Continue

Core Insights - Sanofi's Dupixent sales reached approximately $4.88 billion in Q3, surpassing analyst expectations of $4.64 billion, marking the first time sales exceeded €4 billion [2][4] - Overall, Sanofi reported total sales of about $15.05 billion, with adjusted earnings of $1.69 per share, exceeding forecasts of $14.94 billion and $1.54 respectively [4] - The company maintained its guidance for the year, expecting high single-digit percentage growth in sales and double-digit percentage growth in earnings per share [8] Sales Performance - Dupixent's strong performance helped mitigate a nearly 8% decline in vaccine sales, which fell to about $3.95 billion, missing the forecast of $4 billion [2] - Sales growth for Sanofi's portfolio was 7% in constant currency, while earnings increased by more than 13% [4] Stock Market Reaction - Following the earnings report, Sanofi's stock rose over 4% to $51.70, with a buy point identified at $60.12 [3] Drug Development Updates - Sanofi's oral drug balinatunfib failed in a rheumatoid arthritis study, although expectations were low prior to the results [5] - The company is engaged in ongoing discussions regarding drug pricing with the Trump administration, similar to other pharmaceutical companies [6][7] Future Outlook - Analysts anticipate that Sanofi will follow the lead of Pfizer and AstraZeneca in negotiating drug price reductions with the U.S. government [7] - The company projects earnings per share of $4.49 and total sales of $52.97 billion for the year [8]